Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tibotec initiates recruitment for two Phase III HIV trials
The global trials will compare the efficacy, safety and tolerability of TMC278 (25mg) once daily oral tablet versus efavirenz (EFV), each co-administered with a background regimen of two
The global trials will compare the efficacy, safety and tolerability of TMC278 (25mg) once daily oral tablet versus efavirenz (EFV), each co-administered with a background regimen of two
The contract amount includes $170,000 payable under a letter of intent that was announced previously. The current trial will assess the efficacy and safety of multiple doses of
New investors Legg Mason Capital Management, GE Asset Management and Smallcap World Fund joined current investors Flagship Ventures, Gilde Healthcare Partners, Humana, and Stelios Papadopoulos in the round.
Asubio’s Biopten is said to be a highly pure chemically synthesized form of the tetrahydrobiopterin (BH4) that occurs naturally in the human body. It treats hyperphenylalaninemia (HPA) patients
This will result in the Bellus Health Group owning 100% of the capital stock, thereby acquiring all of the business of Innodia including the intellectual property assets related
Premier will focus on corporate imaging and creating retail market awareness for the existing and new shareholder base. Jing Wang, CEO and president of Huifeng, said: “We believe
The agreement provides Intermedica with the rights to sell in Russia, Belarussia, Kazakstan and the Ukraine, and includes minimum purchase requirements. The Sonablate SB500, a high intensity focused
Mr Merselis will also serve as a member of the company’s board of directors. Most recently, Mr Merselis served as president and CEO of HemoSense, a point-of-care diagnostics
Dr Khankari joins the company from Cima Labs, a Cephalon company, where he served as general manager and vice president for worldwide drug delivery technologies. Dr Khankari earned
Galderma’s Differin gel 0.1% will be marketed in Japan by Galderma KK, the fully-owned Japanese arm of Galderma, and strategic alliance partner Shionogi. Approval was based on non-clinical